Literature DB >> 6254886

Immunity to herpes simplex virus type 2: cell-mediated immunity in latently infected guinea pigs.

A D Donnenberg, E Chaikof, L Aurelian.   

Abstract

Cell-mediated (CMI) and humoral immunity to herpes simplex virus type 2 (HSV-2) were evaluated in infected strain 13/N guinea pigs with (45%) and without a history of recurrent herpetic disease. Virus was isolated by cocultivation from active herpetic lesions (9 of 10) as well as from the footpads (17 of 38), sacral ganglia (7 of 21), and sciatic nerves (1 of 21) of asymptomatic animals. Viral isolates grew in cells of human origin and were neutralized by hyperimmune anti HSV-2 sera. Humoral immunity measured by the presence of virus-neutralizing antibody was similar in both experimental groups. The involvement of CMI in recurrent disease was assessed by comparing lymphocyte transformation (LT) and leukocyte migration inhibition factor (LIF) responses in animals with a history of recurrent disease studied while asymptomatic (quiescent) and in animals without clinical evidence of recurrent disease (seropositive controls). Spleen cells from quiescent animals evidenced significant impairment of both LIF and LT responses as reflected in the requirement of higher antigen concentrations (up to 58-fold) and longer in vitro culture periods (up to 2.5 days) to mount responses comparable in magnitude to those observed in the seropositive control groups. Peripheral blood lymphocyte cultures obtained from quiescent animals showed similar impairment of LIF responses but displayed intact LT response. The data suggest that recurrent disease is associated with an impairment in the generation of anamnestic effector functions as reflected by altered kinetics and dose response patterns in in vitro secondary responses.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6254886      PMCID: PMC551282          DOI: 10.1128/iai.30.1.99-109.1980

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  34 in total

1.  Herpesvirus hominis infection in patients with myeloproliferative and lymphoproliferative disorders.

Authors:  D L Aston; A Cohen; M A Spindler
Journal:  Br Med J       Date:  1972-11-25

2.  Antibody to genital herpes simplex virus: association with cervical atypia and carcinoma in situ.

Authors:  L Aurelian; I Royston; H J Davis
Journal:  J Natl Cancer Inst       Date:  1970-09       Impact factor: 13.506

3.  A prospective study of chronic herpes simplex virus infection and recurrent herpes labialis in humans.

Authors:  R G Douglas; R B Couch
Journal:  J Immunol       Date:  1970-02       Impact factor: 5.422

4.  Variability of herpes simplex virus: isolation of two variants from simultaneous eruptions at different sites.

Authors:  M Terni; B Roizman
Journal:  J Infect Dis       Date:  1970-02       Impact factor: 5.226

5.  Macrophages and age-dependent resistance to Herpes simplex virus in mice.

Authors:  M S Hirsch; B Zisman; A C Allison
Journal:  J Immunol       Date:  1970-05       Impact factor: 5.422

6.  Macrophage migration from an agarose droplet: development of a micromethod for assay of delayed hypersensitivity.

Authors:  J T Harrington; P Stastny
Journal:  J Immunol       Date:  1973-03       Impact factor: 5.422

7.  Characterization of herpes simplex virus strains differing in their effects on social behaviour of infected cells.

Authors:  P M Ejercito; E D Kieff; B Roizman
Journal:  J Gen Virol       Date:  1968-05       Impact factor: 3.891

8.  Herpes virus in the lacrimal gland, conjunctiva and cornea of man--a chronic infection.

Authors:  H E Kaufman; D C Brown; E D Ellison
Journal:  Am J Ophthalmol       Date:  1968-01       Impact factor: 5.258

9.  Immuno-regulatory role of spleen localizing thymocytes.

Authors:  R K Gershon; E M Lance; K Kondo
Journal:  J Immunol       Date:  1974-02       Impact factor: 5.422

10.  Cell-mediated immunity in Herpesvirus hominis infections.

Authors:  J M Wilton; L Ivanyi; T Lehner
Journal:  Br Med J       Date:  1972-03-18
View more
  10 in total

1.  Antiviral activity of 5-ethyl-2'-deoxyuridine against herpes simplex viruses in cell culture, mice, and guinea pigs.

Authors:  R F Schinazi; R T Scott; J Peters; V Rice; A J Nahmias
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

2.  Zinc and genital infections.

Authors:  M S Cornell; L J Hinks; H S Singha; V Walker; F E Willmott
Journal:  Genitourin Med       Date:  1987-08

3.  Immunity to herpes simplex virus type 2: recurrent lesions are associated with the induction of suppressor cells and soluble suppressor factors.

Authors:  T Iwasaka; J F Sheridan; L Aurelian
Journal:  Infect Immun       Date:  1983-12       Impact factor: 3.441

4.  Latency of herpes simplex virus in ocular tissue of mice.

Authors:  H Openshaw
Journal:  Infect Immun       Date:  1983-02       Impact factor: 3.441

5.  Reactivation of latent herpes simplex virus-1 (HSV) from mouse footpad cells demonstrated by in situ hybridization.

Authors:  G B Clements; F E Jamieson
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

Review 6.  Herpes simplex virus type 2 vaccines: new ground for optimism?

Authors:  L Aurelian
Journal:  Clin Diagn Lab Immunol       Date:  2004-05

7.  Animal studies on the efficacy of vaccination against recurrent herpes.

Authors:  M Scriba
Journal:  Med Microbiol Immunol       Date:  1982       Impact factor: 3.402

8.  Pathogenesis of Herpes simplex virus infections in guinea pigs.

Authors:  M Scriba; F Tatzber
Journal:  Infect Immun       Date:  1981-12       Impact factor: 3.441

9.  Antigen-specific immune-suppressor factor in herpes simplex virus type 2 infections of UV B-irradiated mice.

Authors:  L Aurelian; S Yasumoto; C C Smith
Journal:  J Virol       Date:  1988-07       Impact factor: 5.103

Review 10.  Mechanisms and consequences of virus persistence in the human nervous system.

Authors:  V ter Meulen; M J Carter; H Wege; R Watanabe
Journal:  Ann N Y Acad Sci       Date:  1984       Impact factor: 5.691

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.